The author is an analyst for Shinhan Securities. He can be reached at jaewonjeong@shinhan.com -- Ed.2Q23 OP to fall short due to high YoY base in MSD vaccine sales We now expect HK inno.N to post sales of KRW207.1bn (-17.8% YoY) and operating profit of KRW11.5bn (-35.0% YoY, operating margin of 5.5%
A Korea-Japan war seems inevitable in the Korean market for next-generation gastroesophageal reflux disease treatments as Takeda Pharmaceutical, Japan's No. 1 drug maker, is launching its new drug TAKECAB in Korea next month to compete with CJ Healthcare’s K-CAB.Industry watchers said on Feb. 20